A novel mechanism regulating human platelet activation by MMP-2-mediated PAR1 biased signaling

Blood

Volumn 129, Issue 7, 2017, Pages 883-895

  Sebastiano, Manuela ^a   Momi, Stefania ^a   Falcinelli, Emanuela ^a   Bury, Loredana ^a   Hoylaerts, Marc F ^b   Gresele, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTEGRIN; GELATINASE A; HEMOPEXIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEINASE ACTIVATED RECEPTOR 1; FIBRINOGEN RECEPTOR; MMP2 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; ANIMAL; CHO CELL LINE; CRICETULUS; CYTOLOGY; METABOLISM; MOUSE; PROTEIN PROTEIN INTERACTION; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; CHO CELLS; CRICETULUS; HUMANS; MATRIX METALLOPROTEINASE 2; MICE; PLATELET ACTIVATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN INTERACTION MAPS; RECEPTOR, PAR-1; SIGNAL TRANSDUCTION;

EID: 85014973270     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-06-724245     Document Type: Article

References (62)

1. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90(3):251-262.
2. Seizer P, May AE. Platelets and matrix metalloproteinases. Thromb Haemost. 2013;110(5):903-909.
3. Busti C, Falcinelli E, Momi S, Gresele P. Matrix metalloproteinases and peripheral arterial disease. Intern Emerg Med. 2010;5(1):13-25.
4. Chesney CM, Harper E, Colman RW. Human platelet collagenase. J Clin Invest. 1974;53(6):1647-1654.
5. Galt SW, Lindemann S, Allen L, et al. Outside-in signals delivered by matrix metalloproteinase-1 regulate platelet function. Circ Res. 2002;90(10):1093-1099.
6. Kazes I, Elalamy I, Sraer JD, Hatmi M, Nguyen G. Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood. 2000;96(9):3064-3069.
7. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelet activation mediates aggregation. Nature. 1997;386(6625):616-619.
8. Cecchetti L, Tolley ND, Michetti N, Bury L, Weyrich AS, Gresele P. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood. 2011;118(7):1903-1911.
9. Falcinelli E, Guglielmini G, Torti M, Gresele P. Intraplatelet signaling mechanisms of the priming effect of matrix metalloproteinase-2 on platelet aggregation. J Thromb Haemost. 2005;3(11):2526-2535.
10. Momi S, Falcinelli E, Giannini S, et al. Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. J Exp Med. 2009;206(11):2365-2379.
11. Falcinelli E, Giannini S, Boschetti E, Gresele P. Platelets release active matrix metalloproteinase-2 in vivo in humans at a site of vascular injury: lack of inhibition by aspirin. Br J Haematol. 2007;138(2):221-230.
12. Gresele P, Falcinelli E, Loffredo F, et al. Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. Eur Heart J. 2011;32(3):316-325.
13. Lenti M, Falcinelli E, Pompili M, et al. Matrix metalloproteinase-2 of human carotid atherosclerotic plaques promotes platelet activation. Correlation with ischaemic events. Thromb Haemost. 2014;111(6):1089-1101.
14. Soslau G, Mason C, Lynch S, et al. Intracellular matrix metalloproteinase-2 (MMP-2) regulates human platelet activation via hydrolysis of talin. Thromb Haemost. 2014;111(1):140-153.
15. Petrich BG, Marchese P, Ruggeri ZM, et al. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med. 2007;204(13):3103-3111.
16. Choi WS, Jeon OH, Kim HH, Kim DS. MMP-2 regulates human platelet activation by interacting with integrin alphaIIbbeta3. J Thromb Haemost. 2008;6(3):517-523.
17. Vadas O, Dbouk HA, Shymanets A, et al. Molecular determinants of PI3Kγ-mediated activation downstream of G-protein-coupled receptors (GPCRs). Proc Natl Acad Sci USA. 2013;110(47):18862-18867.
18. Coughlin SR. Protease-activated receptors and platelet function. Thromb Haemost. 1999;82(2):353-356.
19. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3(8):1800-1814.
20. Malaquin N, Vercamer C, Bouali F, et al. Senescent fibroblasts enhance early skin carcinogenic events via a paracrine MMP-PAR-1 axis. PLoS One. 2013;8(5):e63607.
21. Lee EJ, Woo MS, Moon PG, et al. Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol. 2010;185(1):615-623.
22. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005;120(3):303-313.
23. Trivedi V, Boire A, Tchernychev B, et al. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell. 2009;137(2):332-343.
24. Jaffré F, Friedman AE, Hu Z, Mackman N, Blaxall BC. β-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells. Circulation. 2012;125(24):2993-3003.
25. Austin KM, Covic L, Kuliopulos A. Matrix metalloproteases and PAR1 activation. Blood. 2013;121(3):431-439.
26. Kakarala KK, Jamil K. Biased signaling: potential agonist and antagonist of PAR2. J Biomol Struct Dyn. 2016;34(6):1363-1376.
27. Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem. 1994;218(2):325-329.
28. Bontadi A, Ruffatti A, Falcinelli E, et al. Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. Thromb Haemost. 2013;109(5):901-908.
29. Stasi M, Gresele P, Porcellati S, Quero E, Nenci GG, Goracci G. Activation of phospholipase A2 and beta-thromboglobulin release in human platelets: comparative effects of thrombin and fluoroaluminate stimulation. Biochim Biophys Acta. 1992;1124(3):279-287.
30. 3 impairs proplatelet formation in human megakaryocytes. PLoS One. 2012;7(4):e34449.
31. Bury L, Falcinelli E, Chiasserini D, Springer TA, Italiano JE Jr, Gresele P. Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia. Haematologica. 2016;101(1):46-56.
32. Adam F, Verbeuren TJ, Fauchère JL, Guillin MC, Jandrot-Perrus M. Thrombin-induced platelet PAR4 activation: role of glycoprotein Ib and ADP. J Thromb Haemost. 2003;1(4):798-804.
33. do Céu Monteiro M, Sansonetty F, Gonçalves MJ, O'Connor JE. Flow cytometric kinetic assay of calcium mobilization in whole blood platelets using Fluo-3 and CD41. Cytometry. 1999;35(4):302-310.
34. Edelheit O, Hanukoglu A, Hanukoglu I. Simple and efficient site-directed mutagenesis using two single-primer reactions in parallel to generate mutants for protein structure-function studies. BMC Biotechnol. 2009;9:61.
35. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64(6):1057-1068.
36. Hung DT, Vu TK, Wheaton VI, Ishii K, Coughlin SR. Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. J Clin Invest. 1992;89(4):1350-1353.
37. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103(6):879-887.
38. Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello CE. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry. 1999;38(14):4572-4585.
39. Seeley S, Covic L, Jacques SL, Sudmeier J, Baleja JD, Kuliopulos A. Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. Chem Biol. 2003;10(11):1033-1041.
40. Zhang C, Srinivasan Y, Arlow DH, et al. High-resolution crystal structure of human protease-activated receptor 1. Nature. 2012;492(7429):387-392.
41. Brass LF, Pizarro S, Ahuja M, et al. Changes in the structure and function of the human thrombin receptor during receptor activation, internalization, and recycling. J Biol Chem. 1994;269(4):2943-2952.
42. Piccard H, Van den Steen PE, Opdenakker G. Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins. J Leukoc Biol. 2007;81(4):870-892.
43. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407(6801):258-264.
44. Maayani S, Schwarz T, Craddock-Royal B, Tagliente TM. Activation of the alpha(2A)-adrenoceptor mediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro. Platelets. 2001;12(6):359-375.
45. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature. 2000;404(6778):609-613.
46. Arachiche A, de la Fuente M, Nieman MT. Calcium mobilization and protein kinase C activation downstream of protease activated receptor 4 (PAR4) is negatively regulated by PAR3 in mouse platelets [published correction appears in PLoS One. 2013;8(12)]. PLoS One. 2013;8(2):e55740.
47. Guglielmini G, Appolloni V, Momi S, et al. Matrix metalloproteinase-2 enhances platelet deposition on collagen under flow conditions. Thromb Haemost. 2016;115(2):333-343.
48. Mastenbroek TG, Feijge MA, Kremers RM, et al. Platelet-associated matrix metalloproteinases regulate thrombus formation and exert local collagenolytic activity. Arterioscler Thromb Vasc Biol. 2015;35(12):2554-2561.
49. Hoxie JA, Ahuja M, Belmonte E, Pizarro S, Parton R, Brass LF. Internalization and recycling of activated thrombin receptors. J Biol Chem. 1993;268(18):13756-13763.
50. Kim S, Foster C, Lecchi A, et al. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood. 2002;99(10):3629-3636.
51. Kowalska MA, Ratajczak MZ, Majka M, et al. Stromal cell-derived factor-1 and macrophage-derived chemokine: 2 chemokines that activate platelets. Blood. 2000;96(1):50-57.
52. Fabre JE, Nguyen M, Athirakul K, et al. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest. 2001;107(5):603-610.
53. Gresele P, Falcinelli E, Momi S. Potentiation and priming of platelet activation: a potential target for antiplatelet therapy. Trends Pharmacol Sci. 2008;29(7):352-360.
54. Mihara K, Ramachandran R, Renaux B, Saifeddine M, Hollenberg MD. Neutrophil elastase and proteinase-3 trigger G protein-biased signaling through proteinase-activated receptor-1 (PAR1). J Biol Chem. 2013;288(46):32979-32990.
55. Zhao P, Lieu T, Barlow N, et al. Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4. J Biol Chem. 2014;289(39):27215-27234.
56. Rasmussen UB, Gachet C, Schlesinger Y, et al. A peptide ligand of the human thrombin receptor antagonizes alpha-thrombin and partially activates platelets. J Biol Chem. 1993;268(19):14322-14328.
57. Hollenberg MD, Mihara K, Polley D, et al. Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease. Br J Pharmacol. 2014;171(5):1180-1194.
58. Brooks PC, Strömblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 1996;85(5):683-693.
59. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995;270(10):5331-5338.
60. Chetty C, Lakka SS, Bhoopathi P, Rao JS. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer. 2010;127(5):1081-1095.
61. Iyer S, Visse R, Nagase H, Acharya KR. Crystal structure of an active form of human MMP-1. J Mol Biol. 2006;362(1):78-88.
62. De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem. 2001;276(7):4692-4698.